# Activaero

Startup profile on Capital Atlas: https://capitalatlas.ai/startups/activaero

- Industry: Medical Devices & Equipment
- Headquarters: Germany
- Website: www.activaero.de
- Total disclosed funding: $23M
- Latest round: Series A (Feb 16, 2011)
- Investors on record: 6

## About

Activaero GmbH, based in Germany, specializes in innovative aerosol delivery technologies for pharmaceutical applications, enhancing drug delivery systems for improved patient outcomes.Founded in 1998, Activaero GmbH operates in the healthcare sector, focusing on aerosol technology for respiratory and other medical applications. The company has undergone changes in its strategic direction to enhance its product offerings and market presence. Activaero has received significant investment, notably a TRADE SALE of EUR 130.000 mn from Vectura Group Plc on March 21, 2014, which addressed its funding needs. The company has completed a total of 4 deals to date.Activaero GmbH specializes in aerosol delivery systems designed to improve the effectiveness of pharmaceutical treatments, particularly for respiratory conditions. Their products aim to ensure precise drug administration to enhance patient outcomes. Activaero's technology is utilized in various applications, making it an important player in the global healthcare technology market, particularly in Europe and North America.Activaero generates revenue through the sale of its aerosol delivery devices and related technology to healthcare providers and pharmaceutical companies. The revenue model includes direct sales to hospitals and clinics, as well as partnerships with other companies that integrate Activaero's technology into their product offerings. This strategy allows for flexible pricing structures based on demand and usage.Activaero aims to expand its product lineup with the introduction of next-generation aerosol devices expected to launch in late 2024. The company is also targeting market expansion into Asia by 2025, focusing on countries with growing healthcare needs. The recent TRADE SALE funding will be utilized to support research and development for new products and to establish partnerships in the Asian market.

## Funding rounds

- Series A, Feb 16, 2011, $6.8M — EQT Life Sciences, BioMed Partners, Vesalius Biocapital, BayBG, Abalis Finance
- Series A, Oct 29, 2009, $16M — BioMed Partners, Vesalius Biocapital, Vi Partners, Abalis Finance

## Investors

- BioMed Partners (https://capitalatlas.ai/funds/biomed-partners) — Series A
- Vesalius Biocapital (https://capitalatlas.ai/funds/vesalius-biocapital) — Series A
- Vi Partners (https://capitalatlas.ai/funds/vi-partners) — Series A
- Abalis Finance — Series A
- EQT Life Sciences (https://capitalatlas.ai/funds/eqt-life-sciences) — Series A
- BayBG (https://capitalatlas.ai/funds/baybg) — Series A